Page 42 – Public Health Update

Joint statement by UNICEF Executive Director and WHO Director-General on the occasion of World Breastfeeding Week

by Public Health Update August 7, 2023

Statement by Catherine Russell and Dr Tedros Adhanom Ghebreyesus

1 August 2023, Joint News Release, Geneva/New York

In the last 10 years, many countries have made significant progress to increase exclusive breastfeeding rates. Yet even greater progress is possible when breastfeeding is protected and supported, particularly in the workplace.

This World Breastfeeding Week, under its theme, “Let’s make breastfeeding at work, work” – UNICEF and WHO are emphasizing the need for greater breastfeeding support across all workplaces to sustain and improve progress on breastfeeding rates globally.

In the last decade, the prevalence of exclusive breastfeeding has increased by a remarkable 10 percentage points, to 48 per cent globally. Countries as diverse as Cote d’Ivoire, Marshall Islands, the Philippines, Somalia and Viet Nam have achieved large increases in breastfeeding rates, showing that progress is possible when breastfeeding is protected, promoted, and supported.

However, to reach the global 2030 target of 70 percent, the barriers women and families face to achieve their breastfeeding goals must be addressed.

Supportive workplaces are key. Evidence shows that while breastfeeding rates drop significantly for women when they return to work, that negative impact can be reversed when workplaces facilitate mothers to continue to breastfeed their babies.

Family-friendly workplace policies – such as paid maternity leave, breastfeeding breaks, and a room where mothers can breastfeed or express milk – create an environment that benefits not only working women and their families but also employers. These polices generate economic returns by reducing maternity-related absenteeism, increasing the retention of female workers, and reducing the costs of hiring and training new staff.

From the earliest moments of a child’s life, breastfeeding is the ultimate child survival and development intervention. Breastfeeding protects babies from common infectious diseases and boosts children’s immune systems, providing the key nutrients children need to grow and develop to their full potential. Babies who are not breastfed are 14 times more likely to die before they reach their first birthday than babies who are exclusively breastfed.

Supporting breastfeeding in the workplace is good for mothers, babies, and businesses, and that is why UNICEF and WHO are calling on governments, donors, civil society, and the private sector to step up efforts to:

ensure a supportive breastfeeding environment for all working mothers – including those in the informal sector or on temporary contracts – by having access to regular breastfeeding breaks and facilities that enable mothers to continue breastfeeding their children once they return to work;
provide sufficient paid leave to all working parents and caregivers to meet the needs of their young children. This includes paid maternity leave for a minimum of 18 weeks, preferably for a period of six months or more after birth; and
Increase investments in breastfeeding support policies and programmes in all settings, including a national policy and programme that regulates and promotes public and private sector support to breastfeeding women in the workplace.

Statement by Catherine Russell and Dr Tedros Adhanom Ghebreyesus

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated

August 7, 2023 0 comments

Fact Sheet Health in Data Maternal, Newborn and Child Health Public Health Update

Breastfeeding Facts in Nepal

by Public Health Update August 1, 2023

written by Public Health Update

The 2022 NDHS is a national sample survey that provides up-to-date information on various health indicators. Here are the major findings of NDHS 2022 related to breastfeeding practices in Nepal.

Exclusive breastfeeding has fluctuated over time, with a sharp dip in 2006. However, exclusive breastfeeding has been steadily declining since 2011, from 70% to 56%.
Nationally, only 56% of children age 0–5 months are exclusively breastfed, while 20% receive mixed milk feeding.
Among women who received ANC for their most recent live birth and/or stillbirth, only 52% of women received counseling on breastfeeding.
Almost all children under age 2 (99%) have been breastfed at some point.
Over half (55%) of children are put to the breast within 1 hour of birth, and 59% are exclusively breastfed for the first 2 days after birth.
Both early initiation of breastfeeding and exclusive breastfeeding for the first 2 days after birth are lower among cesarean section births (17% and 21%, respectively) than among vaginal births (63% and 68%, respectively).
The percentage of children who were put to the breast within 1 hour is higher in rural areas (63%) than in urban areas (51%).
The percentage of children breastfed within 1 hour of birth is highest in Sudurpashchim Province (69%) and lowest in Bagmati Province (43%).
Similarly, 82% of children in Sudurpashchim Province are exclusively breastfed for the first 2 days after birth, as compared with 48% of children in Bagmati Province.
The proportions of children breastfed within 1 hour of birth and exclusively breastfed for the first 2 days are highest in the lowest wealth quintile (62% and 82%, respectively) and lowest in the highest wealth quintile (41% and 40%, respectively).
Early initiation of breastfeeding and exclusive breastfeeding for the first 2 days also vary according to mother’s education.
Sixty-one percent of children born to mothers with no education were put to the breast within 1 hour and 58% were exclusively breastfed for the first 2 days, whereas the corresponding figures among children born to mothers with more than a secondary education are 36% and 32%.

Exclusive Breastfeeding and Mixed Milk Feeding

At age 0–1 month, only 70% of children are exclusively breastfed as per WHO recommendations.
Twenty-eight percent of children are not being fed according to recommended guidelines, with 6% receiving breast milk and plain water only, 1% receiving breast milk and non-milk liquids, 18% receiving breast milk and formula and/or animal milk, and 3% receiving breast milk and solid, semisolid, or soft foods.
By age 2–3 months, there is a small decline in the percentage of children exclusively breastfed, with more than one-third (33%) of children receiving liquids or foods other than breast milk.
By age 4–5 months, the percentage of children exclusively breastfed declines sharply to 41% and the majority of children are receiving liquids or foods other than breast milk, primarily breast milk and solid, semisolid, or soft foods (26%).
Exclusive breastfeeding is highest in Sudurpashchim Province and Karnali Province (74% each) and lowest in Lumbini Province (36%).
The proportion of children age 0–5 months who are exclusively breastfed fluctuates across wealth quintiles.
The proportion is highest in the lowest wealth quintile (64%) and lowest in the highest quintile (44%).
Twenty-two percent of children born in a health facility receive mixed milk feeding (breast milk and fresh, packaged, or powdered animal milk or infant formula), as compared with 12% of those born at home.
Children of mothers with a secondary education more often receive mixed milk feeding than children of mothers with no education (28% versus 9%).

Continued Breastfeeding and Bottle Feeding

Among children age 12–23 months, 94% are currently breastfeeding. Around one-fifth (22%) of children less than age 2 are bottle fed.
The proportion of children who are bottle fed is higher in urban areas (26%) than in rural areas (15%).
Use of a bottle with a nipple is lowest in Karnali Province (11%) and Madhesh Province (12%) and highest in Bagmati Province (43%).
The proportion of children who are bottle fed increases with increasing mother’s education, from 12% among those whose mothers have no education to 49% among those whose mothers have more than a secondary education.
Use of a bottle with a nipple is highest in the highest wealth quintile (46%) and lowest in the lowest quintile (11%).

Introduction of Complementary Foods

Overall, 85% of children were introduced to solid, semisolid, or soft foods at age 6–8 months.
Sixty-seven percent of these breastfeeding children received food made from grains; 66% received beans, peas, lentils, nuts, and seeds; 26% received white/pale starchy roots, tubers, and plantains; 18% received vitamin A-rich fruits and vegetables; 11% received eggs; 5% received meat, fish, poultry, or organ meats; and 30% received other fruits and vegetables.

August 1, 2023 0 comments

Global Health News Public Health News Public Health Update

Information on the election of WHO Regional Directors

by Public Health Update July 28, 2023

written by Public Health Update

The process for electing the Regional Directors of the Eastern Mediterranean (EMR), South East Asia (SEAR) and Wester Pacific (WPR) regions of WHO, respectively, started in Spring 2023. Regional Directors are appointed by the Executive Board, in agreement with the relevant Regional Committee.

The nomination of new Regional Directors will take place at their respective Regional Committees in Fall 2023 (EMR 70th Regional Committee: 9 – 12 October Cairo, Egypt; WPR 74th Regional Committee: 16 – 20 October: Manila – Philippines; SEAR 76th Regional Committee: 30 October – 2 November: New Delhi, India).

The appointment of the Regional Directors will take place at the 154th session of the WHO Executive Board in January 2024.

In the coming weeks, WHO regional offices concerned (EMRO, SEARO and WPRO) will post information on the Regional Director election processes, including the names of the persons proposed for the post of Regional Directors, on their respective websites:

EMRO – on or after 30 July:

https://www.emro.who.int/about-who/regional-director/election-of-regional-director-2023.html

WPRO – on or after 4 August:

https://www.who.int/westernpacific/about/governance/nomination-of-the-regional-director

SEARO – on or after 18 August:

https://www.who.int/southeastasia/about/governance/regional-director/election-of-regional-director-2023

July 28, 2023 0 comments

PH Important Day Public Health News Public Health Update World News

World Hepatitis Day: Accelerate hepatitis testing and treatment

by Public Health Update July 28, 2023

written by Public Health Update

By Dr Poonam Khetrapal Singh, WHO Regional Director for South-East Asia

To mark World Hepatitis Day, WHO is urging policy makers, health care providers and political and civil society leaders in the South-East Asia Region and globally to accelerate hepatitis testing and treatment, recognizing that everyone, everywhere has just ‘One life’ and ‘one liver’ – the theme of this year’s event.

WHO launches “One life, one liver” campaign on World Hepatitis Day

Globally, an estimated 354 million people live with chronic hepatitis B and C and nearly 1.1 million die annually from hepatitis-related complications such as liver cirrhosis and cancer. Hundreds of millions of people with hepatitis remain unaware of their status, which is why for decades it has been referred to as the ‘silent killer’. Safe and effective vaccines can prevent hepatitis B and antiviral drugs can manage chronic hepatitis B and cure most cases of hepatitis C. However, to achieve these outcomes and eliminate hepatitis as a public health threat by 2030 – the Sustainable Development Goal target – access to prompt and accurate testing is required.

World Hepatitis Day

The South-East Asia Region accounts for around 20% of the global hepatitis mortality burden. An estimated 81% of all hepatitis deaths in the Region are attributable to hepatitis B and C. An estimated 60 million people live with chronic hepatitis B and about 10.5 million live with chronic hepatitis C. Every year, the Region sees almost half a million new hepatitis B and C infections – about one every minute.

Nine countries of the Region have achieved coverage of more than 90% of the third dose of hepatitis B vaccine. Eight countries now also provide the hepatitis B vaccine birth dose. To date, four countries have controlled hepatitis B through vaccination. However, timely access to testing and treatment for hepatitis B and C continues to lag. Just 10.5% of people who are eligible for treatment of hepatitis B know their status, and just 4.5% are on treatment. For hepatitis C, just 6.9% of people eligible for treatment know their status, and of them, just 23% have access to treatment.

To accelerate Region-wide access to hepatitis testing and treatment, WHO is calling for action in several key areas. First, policy makers should incorporate hepatitis testing and treatment into packages of essential primary health care services, recognizing that testing and treatment must be accessible within the community, close to where people live and work, and included as part of universal health coverage.

Second, health and community leaders should reach out to, empower and engage vulnerable and high-risk communities specifically, and people from all walks of life generally, building on the immense success of similar initiatives for HIV, as well as the Region’s ‘Nothing for us, without us’ approach.

Third, policy makers and health care providers – including in the private sector – should actively integrate services for hepatitis, HIV and sexually transmitted infections (STIs), in alignment with the Region’s integrated Action Plan for Viral Hepatitis, HIV and STIs 2022–2030, and with a focus on increasing efficiency and reducing gaps and fragmentation.

Fourth, countries should realign – as appropriate – the funding allocated to each of the three diseases, with a focus on delivering maximum impact, based on current disease burdens.

Our targets are ambitious but achievable. By 2030, we must achieve a 90% reduction in new chronic hepatitis infections and a 65% reduction in hepatitis mortality. We must eliminate hepatitis as a public health threat. On World Hepatitis Day, WHO reiterates its support to all countries of the Region to accelerate rapid, strategic and equitable progress, for healthier livers and healthier lives.

28 July 2022 Statement [WHO SEARO]

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

July 28, 2023 0 comments

Global Health News Public Health News Public Health Update World News

WHO launches “One life, one liver” campaign on World Hepatitis Day

by Public Health Update July 28, 2023

written by Public Health Update

Geneva, 28 July: To mark World Hepatitis Day, WHO is calling for scaling up testing and treatment for viral hepatitis, warning that the disease could kill more people than malaria, tuberculosis, and HIV combined by 2040, if current infection trends continue.

Hepatitis causes liver damage and cancer and kills over a million people annually. Of the 5 types of hepatitis infections, hepatitis B and C cause most of the disease and deaths. Hepatitis C can be cured; however, only 21% of people living with hepatitis C infection are diagnosed and only 13% have received curative treatment. Just 10% of people living with chronic hepatitis B are diagnosed, and only 2% of those infected are receiving the lifesaving medicine.

Under the theme of “One life, one liver”, WHO’s World Hepatitis Day campaign highlights the importance of protecting the liver against hepatitis for living a long, healthy life. Good liver health also benefits other vital organs – including the heart, brain and kidneys – that rely on the liver to function.

“Millions of people are living with undiagnosed and untreated hepatitis worldwide, even though we have better tools than ever to prevent, diagnose and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “WHO remains committed to supporting countries to expand the use of those tools, including increasingly cost-effective curative medication, to save lives and end hepatitis.”

WHO will share new guidance to track countries’ progress on the path to the elimination of hepatitis by 2030. To reduce new infections and deaths from hepatitis B and C, countries must: ensure access to treatment for all pregnant women living with hepatitis B, provide hepatitis B vaccines for their babies at birth, diagnose 90% of people living with hepatitis B and/or hepatitis C, and provide treatment to 80% of all people diagnosed with hepatitis. They must also act to ensure optimal blood transfusion, safe injections and harm reduction.

Vaccination, testing and treatment – vital opportunities to protect your liver from hepatitis

The reduction of hepatitis B infections in children through vaccination is a key intervention to limit viral hepatitis infections overall. The target for hepatitis B incidence is the only Sustainable Development Goals’ (SDG) health target that was met in 2020 and is on track for 2030. However, many countries in Africa do not have access to the birth dose hepatitis B vaccines. Gavi’s recent restart of its Vaccine Investment Strategy 2018 – which includes the birth dose hepatitis B vaccine – will jumpstart newborn vaccination programmes in west and central Africa, where mother-to-child hepatitis B transmission rates remain very high.

To help eliminate mother-to-child transmission, WHO recommends that all pregnant women should be tested for hepatitis B during their pregnancy. If positive, they should receive treatment and vaccines should be provided to their newborns. However, a new WHO report shows that of the 64 countries with a policy, only 32 countries reported implementing activities to screen for and manage hepatitis B in antenatal clinics.

The report also shows that of the 103 countries that reported, 80% have policies to screen and manage hepatitis B in HIV clinics, with 65% doing the same for hepatitis C. Increasing hepatitis testing and treatment within HIV programmes will protect people living with HIV from developing liver cirrhosis and liver cancer.

After years of increasing treatment rates, the rise in the number of people accessing hepatitis C curative treatment is slowing. WHO advocates for taking advantage of price reductions in medication to reaccelerate progress in expanding treatment. A 12-week course of medication to cure hepatitis C now costs 60 US dollars for low-income countries, down from the original costs of more than 90 000 US dollars when first introduced in high-income countries. Treatment for hepatitis B costs less than 30 US dollars per year ($2.4 US dollars per month).

For people who want to maintain liver health, WHO recommends hepatitis testing, treatment if diagnosed, and vaccination against hepatitis B. Reducing alcohol consumption, achieving a healthy weight, and managing diabetes or hypertension also benefit liver health.

https://www.who.int/news/item/28-07-2023-who-launches–one-life–one-liver–campaign-on-world-hepatitis-day

July 28, 2023 0 comments

Public Health Opportunity! Explore world's trending global health opportunities! Visit us for latest public health opportunities.

Call for Proposal, EOI & RFP Maternal, Newborn and Child Health Public Health Opportunities Public Health Opportunity

Call for experts: Technical Advisory Group on Maternal Mortality and Maternal Cause of Death Estimation

by Public Health Update July 27, 2023

written by Public Health Update

The World Health Organization (WHO) is seeking experts to serve as members of the Technical Advisory Group on Maternal Mortality and Maternal Cause of Death Estimation. This “Call for experts” provides information about the advisory group in question, the expert profiles being sought, the process to express interest, and the process of selection.

Background

WHO is the leading agency of the United Nations (UN) Maternal Mortality Estimation Inter-Agency Group (MMEIG), a UN initiative comprising WHO, UNICEF, UNFPA, the World Bank Group and the UNDESA/Population Division. The MMEIG has the function to update the inter-agency estimates of maternal mortality. The MMEIG contributes to monitoring progress towards the achievement of Sustainable Development Goal 3 – “Ensure healthy lives and promote well-being for all at all ages” by producing estimates of the maternal mortality ratio (MMR) (target 3.1.1).

To support WHO’s role in the MMEIG and, ultimately, the MMEIG’s work, WHO hereby establishes a Technical Advisory Group on Maternal Mortality and Maternal Cause of Death Estimation (the “TAG”) that will act as an advisory body to WHO in the field of maternal mortality measurement and maternal cause of death measurement. The TAG will provide guidance in relation to on-going methodological improvements and strategies for reporting and enhancing country level reporting.

Functions of the TAG on Maternal Mortality and Maternal Cause of Death Estimation

In its capacity as an advisory body to WHO, the TAG shall have the following functions:

To provide independent evaluation of the scientific, technical and strategic aspects relating to maternal mortality and maternal cause of death measurement and estimation methods.
To recommend priorities relating to the development of a research agenda to address maternal mortality measurement challenges required for global monitoring purposes.
To advise on linkages with related advisory groups, including those working on the measurement and estimation of perinatal, neonatal, and infant mortality.
To advise on strategies to promote linkages to broader strategies to strengthen national statistics systems as relates to maternal mortality measurement, including civil registration and vital statistics, standardized coding and classification according to the rules of the International Classification of Diseases (ICD) framework.
To advise on strategies in relation to the effective dissemination and use of the maternal mortality estimates and related products.

Operations of the TAG on Maternal Mortality and Maternal Cause of Death Estimation

The TAG shall normally be expected meet at least once per year, either in-person or virtually at WHO Headquarters in Geneva, Switzerland, usually for 2-3 days each time. Meetings may be convened in other locations if determined by WHO. Additional meetings and/or interim teleconferences may be required of members where input is requested on specific issues.

Active participation is expected from all TAG members, including in working subgroups, teleconferences and interaction via e-mail. TAG members may be requested to review meeting documentation in advance of TAG meetings.

The working language of the TAG will be English.

Who can express interest?

The TAG on Maternal Mortality and Maternal Cause of Death Estimation will be multidisciplinary, with members who have a range of technical knowledge, skills and experience relevant to maternal mortality and morbidity measurement.

WHO welcomes expressions of interest from:

Expert scientists, healthcare professionals, health management information systems and data specialists with expertise in the following areas:
- Epidemiology, biostatistics, data science, modelling of health estimatesMaternal health, obstetrics and gynecology, midwifery, reproductive healthMonitoring and measurement within health systemsCensuses, civil registration and vital statistics, health and demographic surveillance systems, maternal death review, verbal autopsy, other surveillance systems, as relates to mortality and cause of death data
Submitting your expression of interestTo register your interest in being considered for the TAG on Maternal Mortality and Maternal Cause of Death Estimation, please submit the following documents by 1^st September 2023, 23h59 Central European Summer Time (UTC + 2 hours) to maternalestimates@who.int using the subject line “Expression of interest for the TAG on Maternal Mortality and Maternal Cause of Death Estimation”.
- A cover letter, indicating your motivation to apply and how your expertise meets the criteria above. Please note that, if selected, membership will be in a personal capacity. Therefore, do not use the letterhead or other identification of your employer);Your curriculum vitae;One example of a work product or report in the relevant area; andA signed and completed Declaration of Interests (DOI) form for WHO Experts, available HERE.
After submission, your expression of interest will be reviewed by WHO. Due to an expected high volume of interest, only selected individuals will be informed.Important information about the selection processes and conditions of appointmentMembers of WHO advisory groups (AGs) must be free of any real, potential or apparent conflicts of interest.
To this end, applicants are required to complete the WHO Declaration of Interests for WHO Experts, and the selection as a member of an AG is, amongst other things, dependent on WHO determining that there is no conflict of interest or that any identified conflicts could be appropriately managed (in addition to WHO’s evaluation of an applicant’s experience, expertise and motivation and other criteria).All AG members will serve in their individual expert capacity and shall not represent any governments, any commercial industries or entities, any research, academic or civil society organizations, or any other bodies, entities, institutions or organizations. They are expected to fully comply with the Code of Conduct for WHO Experts . AG members will be expected to sign and return a completed confidentiality undertaking prior to the beginning of the first meeting.The selection of members of the AGs will be made by WHO in its sole discretion, taking into account the following (non-exclusive) criteria: relevant technical expertise; experience in international and country policy work; communication skills; and ability to work constructively with people from different cultural backgrounds and orientations .The selection of AG members will also take account of the need for diverse perspectives from different regions, especially from low and middle-income countries, and for gender balance.If selected by WHO, proposed members will be sent an invitation letter and a Memorandum of Agreement. Appointment as a member of an AG will be subject to the proposed member returning to WHO the countersigned copy of these two documents.
WHO reserves the right to accept or reject any expression of interest, to annul the open call process and reject all expressions of interest at any time without incurring any liability to the affected applicant or applicants and without any obligation to inform the affected applicant or applicants of the grounds for WHO’s action.
WHO may also decide, at any time, not to proceed with the establishment of the AG, disband an existing AG or modify the work of the AG.WHO shall not in any way be obliged to reveal, or discuss with any applicant, how an expression of interest was assessed, or to provide any other information relating to the evaluation/selection process or to state the reasons for not choosing a member.
WHO may publish the names and a short biography of the selected individuals on the WHO internet. AG members will not be remunerated for their services in relation to the AG or otherwise.
Travel and accommodation expenses of AG members to participate in AG meetings will be covered by WHO in accordance with its applicable policies, rules and procedures.The appointment will be limited in time as indicated in the letter of appointment, typically for 2 years.If you have any questions about this “Call for experts”, please write to maternalestimates@who.int well before the applicable deadline.

July 27, 2023 0 comments

Drug and Medicine Public Health News Public Health Update

WHO Model Lists of Essential Medicines(EML) 2023

by Public Health Update July 26, 2023

written by Public Health Update

WHO Model Lists of Essential Medicines

The WHO Model Lists of Essential Medicines are updated every two years by the Expert Committee on Selection and Use of Essential Medicines. The first Essential Medicines List was published in 1977, and the first Essential Medicines List for Children was published in 2007. The current versions, updated in July 2023, are the 23^rd Essential Medicines List (EML) and the 9^th Essential Medicines List for Children (EMLc).

List of Essential Medicines for Basic Health Services in Nepal

Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and safety and comparative cost-effectiveness. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.

Selection of a limited number of essential medicines as essential, taking into consideration national disease burden and clinical need can lead to improved access through streamlined procurement and distribution of quality-assured medicines, support more rational or appropriate prescribing and use and lower costs for both health care systems and for patients (WHO).

DOWNLOAD UPDATED (WHO Model List of Essential Medicines – 23rd list, 2023)

Model List of Essential Medicines (WHO Electronic EML)
The eEML is a comprehensive, freely accessible, online database containing information on essential medicines.

Lists of Essential Medicines

BCG vaccine
Japanese encephalitis vaccine
Abacavir
Abacavir + lamivudine
Abacavir + lamivudine + lopinavir + ritonavir
Abiraterone
Acetazolamide
Acetic acid
Acetylcysteine
Acetylsalicylic acid
Aciclovir
Aclidinium
Activated charcoal
Adalimumab
Afatinib
Albendazole
Alcohol based hand rub
Alcuronium
All-trans retinoic acid
Allopurinol
Alteplase
Amidotrizoate
Amikacin
Amiloride
Amiodarone
Amitriptyline
Amlodipine
Amodiaquine
Amodiaquine + sulfadoxine + pyrimethamine
Amoxicillin
Amoxicillin + clavulanic acid
Amphotericin B
Ampicillin
Anakinra
Anastrozole
Anidulafungin
Anti-d immunoglobulin
Anti-rabies immunoglobulin
Anti-rabies virus monoclonal antibodies
Anti-tetanus immunoglobulin
Antirabies hyperimmune serum
Antivenom immunoglobulin
Antivenom sera
Apixaban
Aprepitant
Arsenic trioxide
Artemether
Artemether + lumefantrine
Artesunate
Artesunate + amodiaquine
Artesunate + mefloquine
Artesunate + pyronaridine tetraphosphate
Ascorbic acid
Asparaginase
Atazanavir
Atazanavir + ritonavir
Atenolol
Atezolizumab
Atorvastatin
Atracurium
Atropine
Azacitidine
Azathioprine
Azithromycin
Aztreonam
Barium sulfate
Beclometasone
Beclometasone + formoterol
Bedaquiline
Bendamustine
Benzathine benzylpenicillin
Benznidazole
Benzoic acid + salicylic acid
Benzoyl peroxide
Benzyl benzoate
Benzylpenicillin
Betamethasone
Bevacizumab
Bicalutamide
Binimetinib
Biperiden
Bisacodyl
Bisoprolol
Bleomycin
Bortezomib
Bromocriptine
Budesonide
Budesonide + formoterol
Budesonide + salmeterol
Bupivacaine
Buprenorphine
Bupropion
C1 esterase inhibitor
Cabergoline
Caffeine citrate
Calamine
Calcipotriol
Calcitriol
Calcium
Calcium folinate (leucovorin calcium)
Calcium gluconate
Canagliflozin
Capecitabine
Capreomycin
Captopril
Carbachol
Carbamazepine
Carbetocin
Carbimazole
Carboplatin
Carvedilol
Caspofungin
Cefalexin
Cefazolin
Cefepime
Cefiderocol
Cefixime
Cefotaxime
Ceftaroline
Ceftazidime
Ceftazidime + avibactam
Ceftolozane + tazobactam
Ceftriaxone
Cefuroxime
Cetirizine
Chlorambucil
Chloramphenicol
Chlorhexidine
Chlorine base compound
Chloroquine
Chlorothiazide
Chloroxylenol
Chlorpromazine
Chlortalidone
Chlortetracycline
Cholera vaccine
Ciclesonide
Ciclosporin
Cimetidine
Ciprofloxacin
Cisplatin
Clarithromycin
Clindamycin
Clofazimine
Clomifene
Clomipramine
Clonazepam
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Coagulation factor IX
Coagulation factor VIII
Coal tar
Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate
Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide
Cobimetinib
Codeine
Colchicine
Colecalciferol
Colistin (injection)
Compound sodium lactate solution
Condoms
Copper-containing intrauterine device
Crizotinib
Cyanocobalamin
Cyclizine
Cyclopentolate
Cyclophosphamide
Cycloserine
Cytarabine
Dabigatran
Dabrafenib
Dacarbazine
Daclatasvir
Daclatasvir + sofosbuvir
Dactinomycin
Dalteparin
Dapagliflozin
Dapsone
Daptomycin
Daratumumab
Darbepoetin alfa
Darunavir
Dasabuvir
Dasatinib
Daunorubicin
Deferoxamine
Delafloxacin
Delamanid
Dengue vaccine
Desmopressin
Dexamethasone
Dextran 40
Dextran 70
Diaphragms
Diazepam
Diazoxide
Didanosine
Diethylcarbamazine
Digitoxin
Digoxin
Dihydroartemisinin + piperaquine phosphate
Dihydroergocryptine mesylate
Diloxanide
Dimercaprol
Diphtheria antitoxin
Diphtheria vaccine
Diphtheria-pertussis-tetanus vaccine
Diphtheria-tetanus vaccine
Docetaxel
Docusate sodium
Dolasetron
Dolutegravir
Dolutegravir + lamivudine + tenofovir
Dopamine
Doxorubicin
Doxycycline
Durvalumab
Edoxaban
Efavirenz
Efavirenz + emtricitabine + tenofovir
Efavirenz + lamivudine + tenofovir
Eflornithine
Elbasvir + grazoprevir
Empagliflozin
Emtricitabine
Emtricitabine + rilpivirine + tenofovir alafenamide
Emtricitabine + rilpivirine + tenofovir disoproxil fumarate
Emtricitabine + tenofovir
Emtricitabine + tenofovir alafenamide
Enalapril
Encorafenib
Enoxaparin
Entecavir
Enzalutamide
Ephedrine
Epinephrine
Epoetin alfa
Epoetin beta
Epoetin theta
Equine rabies immunoglobulin
Eravacycline
Ergocalciferol
Ergometrine
Erlotinib
Erythromycin
Erythropoiesis-stimulating agents
Estradiol cypionate + medroxyprogesterone acetate
Ethambutol
Ethambutol + isoniazid
Ethambutol + isoniazid + pyrazinamide + rifampicin
Ethambutol + isoniazid + rifampicin
Ethanol
Ether
Ethinylestradiol + etonogestrel
Ethinylestradiol + levonorgestrel
Ethinylestradiol + norethisterone
Ethionamide
Ethosuximide
Etonogestrel-releasing implant
Etoposide
Everolimus
Fentanyl
Ferrous salt
Ferrous salt + folic acid
Fexinidazole
Fexofenadine
Fifth generation cephalosporins
Filgrastim
Fingolimod
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flunisolide
Fluorescein
Fluoride
Fluorouracil
Fluoxetine
Fluphenazine
Flutamide
Fluticasone
Fluticasone + formoterol
Fluticasone furoate + vilanterol
Fluvastatin
Folic acid
Fomepizole
Fosfomycin (injection)
Fourth generation cephalosporins
Fresh-frozen plasma
Fulvestrant
Furosemide
Gabapentin
Gallamine
Gatifloxacin
Gefitinib
Gemcitabine
Gentamicin
Glass ionomer cement
Glatiramer acetate
Glecaprevir + pibrentasvir
Glibenclamide
Gliclazide
Glucagon
Glucose
Glucose + sodium chloride
Glutaral
Glyceryl trinitrate
Glycopyrronium
Goserelin
Granisetron
Griseofulvin
Haemophilus influenzae type b vaccine
Haloperidol
Halothane
Heparin sodium
Hepatitis a vaccine
Hepatitis b vaccine
Homatropine
Human papilloma virus (HPV) vaccine
Hydralazine
Hydrochlorothiazide
Hydrocortisone
Hydromorphone
Hydroxocobalamin
Hydroxycarbamide (hydroxyurea)
Hydroxychloroquine
Hyoscine butylbromide
Hyoscine hydrobromide
Hypochlorous acid
Ibrutinib
Ibuprofen
Idoxuridine
Ifosfamide
Imatinib
Imipenem + cilastatin
Indapamide
Indinavir
Indometacin
Influenza vaccine (seasonal)
Insulin
Insulin analogues
Insulin degludec
Insulin detemir
Insulin glargine
Intermediate-acting insulin
Intraperitoneal dialysis solution
Iodine
Iohexol
Ipecacuanha
Ipratropium bromide
Irinotecan
Isoflurane
Isoniazid
Isoniazid + pyrazinamide + rifampicin
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim
Isoniazid + rifampicin
Isoniazid + rifapentine
Isoprenaline
Isosorbide dinitrate
Itraconazole
Ivermectin
Kanamycin
Kanamycin (injection)
Ketamine
Lactulose
Lamivudine
Lamivudine + nevirapine + zidovudine
Lamivudine + tenofovir
Lamivudine + zidovudine
Lamotrigine
Latanoprost
Ledipasvir + sofosbuvir
Lenalidomide
Leuprorelin
Levamisole
Levodopa
Levodopa + benserazide
Levodopa + carbidopa
Levofloxacin
Levonorgestrel
Levonorgestrel-releasing implant
Levothyroxine
Lidocaine
Lidocaine + epinephrine
Lindane
Linezolid
Lisinopril + amlodipine
Lisinopril + hydrochlorothiazide
Lithium carbonate
Long-acting insulin analogues
Loperamide
Lopinavir + ritonavir
Loratadine
Lorazepam
Losartan
Lovastatin
Lugol’s solution
Magnesium sulfate
Mannitol
Measles vaccine
Mebendazole
Medroxyprogesterone acetate
Mefloquine
Meglumine antimoniate
Meglumine iotroxate
Melarsoprol
Melphalan
Meningococcal meningitis vaccine
Mercaptopurine
Meropenem
Meropenem + vaborbactam
Mesalazine
Mesna
Metformin
Methadone
Methimazole
Methionine
Methotrexate
Methoxy polyethylene glycol-epoetin beta
Methyldopa
Methylergometrine
Methylphenidate
Methylprednisolone
Methylthioninium chloride
Metoclopramide
Metoprolol
Metronidazole
Micafungin
Miconazole
Midazolam
Mifepristone – misoprostol
Miltefosine
Misoprostol
Mometasone
Mometasone + formoterol
Morphine
Moxifloxacin
Multiple micronutrient powder
Multiple micronutrient supplement
Mumps vaccine
Mupirocin
Nadroparin
Nalidixic acid
Naloxone
Natamycin
Nelfinavir
Neostigmine
Netilmicin
Nevirapine
Niclosamide
Nicotinamide
Nicotine replacement therapy
Nifedipine
Nifurtimox
Nilotinib
Nilutamide
Nitrofurantoin
Nitrous oxide
Nivolumab
Norethisterone
Norethisterone enantate
Normal immunoglobulin
Nystatin
Ocrelizumab
Ofloxacin
Omadacycline
Ombitasvir + paritaprevir + ritonavir
Omeprazole
Ondansetron
Oral rehydration salts
Oral rehydration salts – zinc sulfate
Oseltamivir
Osimertinib
Oxaliplatin
Oxamniquine
Oxazolindinones
Oxycodone
Oxygen
Oxytetracycline
Oxytocin
P-aminosalicylic acid
Paclitaxel
Palbociclib
Paliperidone
Palonosetron
Pancreatic enzymes
Paracetamol (acetaminophen)
Paromomycin
Pegaspargase
Pegylated interferon alfa (2a)
Pegylated interferon alfa (2b)
Pembrolizumab
Penicillamine
Pentamidine
Permethrin
Pertussis vaccine
Pertuzumab
Phenobarbital
Phenoxymethylpenicillin
Phenytoin
Phytomenadione
Pilocarpine
Piperacillin + tazobactam
Platelets
Plazomicin
Pneumococcal vaccine
Podophyllotoxin
Podophyllum resin
Poliomyelitis vaccine
Polygeline
Polymyxin B (injection)
Polymyxins
Potassium chloride
Potassium ferric hexacyanoferrate
Potassium iodide
Potassium permanganate
Povidone iodine
Pralidoxime
Pramipexole
Pravastatin
Praziquantel
Precipitated sulfur
Prednisolone
Prednisone
Primaquine
Probenecid
Procainamide
Procaine benzylpenicillin
Procarbazine
Progesterone vaginal ring
Proguanil
Promethazine
Propanol
Propofol
Propranolol
Propylthiouracil
Prostaglandin E1
Prostaglandin E2
Protamine sulfate
Pyrantel
Pyrazinamide
Pyridostigmine
Pyridoxine
Pyrimethamine
Quinidine
Quinine
Rabies vaccine
Raltegravir
Ranibizumab
Ranitidine
Rasburicase
Ready to use therapeutic food
Realgar-indigo naturalis formulation
Red blood cells
Retinol
Ribavirin
Riboflavin
Rifabutin
Rifampicin
Rifapentine
Risperidone
Ritonavir
Rituximab
Rivaroxaban
Ropinirole
Rotavirus vaccine
Rubella vaccine
Salbutamol
Salicylic acid
Saquinavir
Selenium sulfide
Senna
Silver diamine fluoride
Silver nitrate
Silver sulfadiazine
Simeprevir
Simvastatin
Smallpox vaccine
Snake antivenom
Sodium calcium edetate
Sodium chloride
Sodium hydrogen carbonate
Sodium nitrite
Sodium nitroprusside
Sodium stibogluconate
Sodium thiosulfate
Sofosbuvir
Sofosbuvir + velpatasvir
Spectinomycin
Spironolactone
Stavudine
Streptokinase
Streptomycin (injection)
Succimer
Sulfacetamide
Sulfadiazine
Sulfadoxine + pyrimethamine
Sulfamethoxazole + trimethoprim
Sulfasalazine
Sumatriptan
Suramin sodium
Surfactant
Suxamethonium
Tacalcitol
Tacrolimus
Tamoxifen
Telmisartan + amlodipine
Telmisartan + hydrochlorothiazide
Tenofovir alafenamide
Tenofovir disoproxil fumarate
Terbinafine
Terbutaline
Terizidone
Testosterone
Tetanus antitoxin
Tetanus vaccine
Tetracaine
Tetracycline
Thalidomide
Thiamine
Thiopental
Tick-borne encephalitis vaccine
Tigecycline
Timolol
Tioguanine
Tiotropium bromide
Tislelizumab
Tobramycin
Tocilizumab
Tolbutamide
Tramadol
Trametinib
Tranexamic acid
Trastuzumab
Trastuzumab emtansine
Triamcinolone hexacetonide
Triclabendazole
Trihexyphenidyl
Trimethoprim
Triptorelin
Tropicamide
Tropisetron
Tuberculin, purified protein derivative
Tubocurarine
Typhoid vaccine
Ulipristal
Umeclidinium
Urea
Valaciclovir
Valganciclovir
Valproic acid (sodium valproate)
Vancomycin
Varenicline
Varicella vaccine
Vecuronium
Vemurafenib
Verapamil
Vinblastine
Vincristine
Vinorelbine
Voriconazole
Warfarin
Water for injection
Whole blood
Xylometazoline
Yellow fever vaccine
Zanubrutinib
Zidovudine
Zinc sulfate
Zoledronic acid

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

July 26, 2023 0 comments

Fulbright Foreign Student (Master’s) Program

Fellowships, Studentship & Scholarships International Jobs & Opportunities Opportunities by Region Public Health Opportunities Public Health Opportunity

Hubert H. Humphrey Fellowship Program 2024-2025

by Public Health Update July 26, 2023

written by Public Health Update

Overview

The Commission for Educational Exchange between the United States and Nepal (also known as “the Fulbright Commission” or “USEF/Nepal“) announces the annual competition for the Hubert H. Humphrey Fellowship Program for the 2024-2025 academic year.

The Humphrey Fellowship Program was initiated in 1978 to honor the memory and accomplishments of the late Senator and Vice-President, Hubert H. Humphrey. Fellows are selected through a competitive process based on their potential for leadership and commitment to public service in the public or private sector. Over 6,450 Fellows representing 163 countries have participated in the program since its inception. Approximately 150 Humphrey Fellowships will be awarded for program year 2023- 2024.

Study Fields

These priority fields align with U.S. foreign policy and Mission goals and advance the development of a network of international leaders with experience in the U.S. who serve as key interlocutors for posts.

Human and Institutional Capacity:

Economic Development
Finance & Banking
Public Policy Analysis and Public Administration
Technology Policy and Management

Rights and Freedoms:

Communications/ Journalism
Law and Human Rights

Sustainable Lands:

Agricultural and Rural Development
Natural Resources, Environmental Policy, and Climate Change
Urban and Regional Planning

Thriving Communities:

Public Health Policy and Management
Substance Abuse Education, Treatment and Prevention
Educational Administration, Planning, and Policy

Program Timeline

Date	Milestone
June 16, 2023	Humphrey Fellowship Information Session
11:59 PM (NPT), July 31, 2023	Application deadline
August, 2023	Interviews Selected candidates informed
September, 2023	Selected candidates sit for TOEFL test
February, 2024	ECA reports final selection results
August, 2024	Humphrey Fellowship Program start
June, 2025	End of Fellowship year

Eligibility Requirements

Candidates must be policymakers, managers, or administrators in leadership positions with a commitment to public service from the public or private sectors including non-governmental organizations. Fellowships are competitive and will be awarded on the basis of excellence in professional and personal qualifications as well as leadership potential.

All applicants must

Possess Nepali citizenship;
Be employed at a mid-career, policy level with progressively more responsible working experience in the government, NGO or private sector;
Have at least 5 years of progressively more responsible professional experience in Nepal as of the application submission deadline. Volunteer jobs, internships, and work done as a requirement for an academic degree shall not be counted towards the required duration of work experience;
The professional experience should be in the relevant field, after the completion of a university degree i.e. a 4-year bachelor’s degree, or if the bachelor’s degree is of 2-year/3-year duration, then a master’s degree is also required. Candidates who have two or more 2-year/3-year bachelor’s degrees in different fields but who do not have a master’s degree are ineligible to apply;
Be proficient in speaking, reading and writing English (See the supplemental English program);
Have a demonstrable commitment to public service and potential for national leadership;
Have a wish to develop problem-solving capacities, enhance capabilities to assume greater career responsibilities, and return to a significant public service role upon completion of the Humphrey Program.

The Humphrey competition is not open to:

Recent university graduates (even if they have significant positions);
University teachers with no management or policy responsibilities, except for teachers of English as a foreign language, and specialists in substance abuse prevention and treatment;
Individuals who have spent substantial time in the U.S. (more than 3 years) and have not been back in Nepal and employed at a level of professional responsibility for at least four years since returning;
Individuals who have attended a graduate school in the U.S. for one academic year or more during the seven years prior to August 2024;
Individuals with more than six months of U.S. experience during the five years prior to August 2024;
Individuals who have participated in any State Department exchange program within the last three years;
Individuals with, or in the process of obtaining, dual U.S. citizenship or U.S. permanent resident status are ineligible for a J visa, and
Local employees of the U.S. Mission in Nepal who work for the Department of State, or the U.S. Agency for International Development, including temporary employees and contractors, and their spouses and dependent children (they are ineligible for grants during the period of their employment and for one year following the termination of employment).

Visa sponsorship

All selected Humphrey Fellows receive an exchange visitor (J-1) visa which requires that the individuals return to Nepal upon completion of their fellowship. They are not eligible for an immigrant visa, for permanent residence, or for a non-immigrant visa as a temporary worker (“H” visa) or trainee, or as an intra-company transferee (“L” visa) to re-enter the U.S. until they have accumulated two years’ residence in Nepal after returning from the U.S. on an exchange visitor visa. This does not preclude the individual from going to the U.S. on other visas during the two-year period.

Application Link: https://apply.iie.org/huberthhumphrey

Application deadline- 11:59 PM, July 31, 2023

Official Notice (Nepal)

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

July 26, 2023 0 comments

Global Health News National Health News PH Important Day Public Health News Public Health Update World News

WHO urges countries to invest in drowning prevention to protect children

by Public Health Update July 25, 2023

written by Public Health Update

On World Drowning Prevention Day this year, WHO is releasing an investment case on drowning prevention showing how just two actions – investing in day care for pre-school aged children and teaching basic swim skills to school-age children – could protect millions of lives. Each dollar invested in these actions can yield benefits up to nine times the original value.

Drowning is an under appreciated but lethal public health issue. It has caused over 2.5 million deaths in the last decade, with an alarming 90% of these fatalities occurring in low- and middle-income countries. Across all age groups, children aged 1–4 years and 5–9 years experience the highest drowning rates, highlighting the need for immediate action to protect future generations.

Yet effective solutions exist. The new investment case shows that by 2050, increased global investment in just two measures could save the lives of over 774 000 children, prevent close to 1 million non-fatal child drownings, and avert severe and life-limiting injuries for 178 000 drowning victims.

It could also prevent potential economic losses of over US$400 billion in low- and middle-income countries with high burden, and provide cumulative benefits valued at around US$ 9 for each US$ 1 invested. Countries such as Bangladesh, South Africa, Thailand and Viet Nam have already invested in these cost-effective interventions, benefitting children and their families by reducing their risk of drowning, while simultaneously providing new opportunities for improved health, development and wellbeing.

“By implementing effective preventive measures, increasing investments, and promoting awareness, we can save countless lives,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. «As we observe World Drowning Prevention Day today, we ask countries and partners to join hands to make drowning prevention a global priority.”

In May 2023, the World Health Assembly (WHA) adopted its first-ever resolution on drowning prevention. This resolution invites WHO to lead efforts within the United Nations system to prevent drowning and facilitate the observance of World Drowning Prevention Day on July 25th each year.

As requested in the WHA resolution, WHO is launching the Global Alliance for Drowning Prevention. The Alliance is a network of partners who will work together to coordinate, strengthen, enhance, and expand efforts to prevent drowning deaths, aligned with WHO’s priorities. The Alliance operates under the principles of alignment and coordination, agility and responsiveness, driving country-level action, transparency, evidence-based approaches, and coordination among interested parties.

“Over the past decade, drowning has killed more than 2.5 million people,” said Michael R. Bloomberg, founder of Bloomberg LP and Bloomberg Philanthropies and World Health Organization Global Ambassador for Noncommunicable Diseases and Injuries. “Bloomberg Philanthropies has been working with our partners to implement proven life-saving solutions, like teaching basic swimming survival skills and providing child care. Now, by bringing together governments and partners from around the world, we can help spread this work and save many more lives.”

WHO is also preparing a global status report on drowning prevention to better understand the impact of drowning and analyze government actions worldwide. The global status report will provide critical information for policy-makers and programme managers to catalyze more action to implement low-cost, scalable and effective drowning prevention interventions recommended by WHO, with all 194 Member States invited to participate.

25 July 2023 News release

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

July 25, 2023 0 comments

Grants and Funding Opportunities International Jobs & Opportunities Opportunities by Region PostDoc Public Health Opportunities Public Health Opportunity

UNU-International Institute for Global Health Post Doctoral Fellow

by Public Health Update July 25, 2023

written by Public Health Update

The United Nations University (UNU) is an international community of scholars engaged in policy-oriented research, capacity development and dissemination of knowledge, furthering the purposes and principles of the Charter of the United Nations. UNU’s mission is to contribute, through research and capacity building, to efforts to resolve the pressing global problems that are the concern of the United Nations and its Member States.

For the past four decades, United Nations University (UNU) has been a go-to think tank for impartial research on human survival, conflict prevention, sustainable development and welfare. With more than 400 researchers in 12 countries, UNU’s work spans the 17 Sustainable Development Goals, generating policy-relevant knowledge to effect positive global change. UNU maintains more than 200 collaborations with UN agencies and leading universities and research institutions across the globe.

About Institute (UNU-IIGH)

UNU-International Institute for Global Health is one of 13 research and training Institutes that comprise the think tanks in the UNU system. UNU-IIGH was established in 2005 with the mission to advance evidence-based policy on key issues related to sustainable development and global health. UNU-IIGH aims to build knowledge and capacity for decision making by UN agencies, UN programmes and Member States towards the achievement of the Sustainable Development Goals.

Leveraging its position within the UN, UNU-IIGH works with a network of academic, policy and civil society experts to serve as a platform for critical thinking and exchange of knowledge and tools for policy influence and consensus-building.

This post-doctoral fellow position is open for a candidate with an interest in global health policy and governance and the interface between global health institutions and country-level actors. The successful candidate will contribute to a programme of work within UNU-IIGH aimed at addressing accountability deficits within the global health system and enabling initiatives directed towards a decolonisation of global health.

Generic Responsibilities of a Post-doctoral Fellow

1. Conducting research in support of the Institute’s programme of work focusing on:

This may include the production of relevant analysis and guidance, conducting literature searches and reviews; designing research studies; and collecting and analyzing primary data.

2. Drafting and helping to finalise research outputs of various kinds

This may include policy briefs, blogs, academic journal papers and internal briefing papers.

3. Helping to convene multi-stakeholder meetings and discussions focusing on the achievement of the following results

This may include the design and management of logistical arrangements, handling communication with external stakeholders, writing up minutes of meetings and conversations, and facilitating collaborative partnership work amongst participating actors

4. Contributing to information, education and communication activities

This may include developing teaching slides and other types of educational material, contributing to IIGH’s website, and enhancing IIGH’s social media profile

5. Contributing to the routine management and administrative tasks of the Institute

This may include contributing to IIGH’s internal reporting obligations, preparing and chairing internal management meetings, and organizing internal seminars.

Key performance indicators

Timely production of high-quality research and research outputs
Demonstrable improvements in project management competencies
Successful organization of meetings with external stakeholders
Development of improved working relationships with research partners, member state governments, donors, and civil society organizations

Competencies

Values:

Inclusion — take action to create an environment of dignity and respect for all, regardless of age, culture, disability, ethnicity, gender, gender identity, gender expression, geography, grade, language, nationality, racial identity, religion, sex, sex characteristics, sexual orientation, social origin or any other aspect of identity
Integrity — act ethically, demonstrating the standards of conduct of the United Nations and taking prompt action in case of witnessing unprofessional or unethical behaviour, or any other breach of UN standards
Humility — demonstrate self-awareness and willingness to learn from others
Humanity — act according to the purposes of the United Nations: peace, dignity and equality on a healthy planet

Behaviours:

Connect and collaborate — build positive relationships with others to advance the work of the United Nations and work coherently as One UN
Analyse and plan — seek out and use data from a wide range of sources to understand problems, inform decision-making, propose evidence-based solutions and plan action
Deliver results with positive impact — hold oneself and others accountable for delivering results and making a positive difference to the people and causes that the United Nations serves
Learn and develop — pursue own learning and development and contribute to the learning and development of others
Adapt and innovate — demonstrate flexibility, agility and the ability to think and act in novel ways

Qualifications

Education and certification

Required

PhD in public health or relevant field (completed within the last five years), or an MD with a relevant Masters’ degree. Applicants who have submitted their PhD but have not yet been awarded their degree may also be eligible to apply.

Experience

Required

At least one year of professional experience in public health research, policy, or programming
Familiarity with systematic approaches to searching and evaluating scientific literature
Masters level competencies in both quantitative and qualitative research
Experience in policy research and writing policy briefs
Excellent oral and written communication skills in English
Excellent time management skills

Desired

• Experience in working on interdisciplinary research projects

• Experience in writing peer-reviewed manuscripts

• Knowledge of global health governance structures and processes

• Experience of work in a low and middle income country setting

• Interest in gender-responsive research and/or programming

• Ability to work independently

Language Requirements

Oral and written fluency in English is required
Knowledge of another UN official working language is an asset.

Remuneration

The successful candidate will be employed under a PSA contract and no allowances apply. UNU offers an attractive compensation package, including a monthly salary of US$3,028.92, commensurate with the candidate’s experience and qualifications. Benefits include 30 days of annual leave and a health insurance scheme.

UNU will cover the cost of travel of the individual to the duty station and their return to their home upon completion of their services. Travel costs are covered only if the function is undertaken physically in the duty station and excludes working-from-home arrangements.

UNU is not liable for any taxes that may be levied on the remuneration you receive under this contract. Payment of any such taxes remains the sole responsibility of PSA holders.

Duration of contract

This is full-time employment. The duration of the initial contract is 1 year, which can be extended for an additional 12-month period.

Expected start date: 1 January 2024

How to Apply:

To apply to UNU, you will not need an account. Instead, we ask that you:

Apply via the apply link;
fill out the UNU P11 form (please avoid using similar forms provided by other United Nations organisations);
provide a motivation statement (in the P11 form); and
answer a few questions that are tailored to the position.

You may wish to refer to the UN Values and Behaviours Framework for more information.

Application Deadline: 20 August 2023

Assessment

Evaluation of qualified candidates may include an assessment exercise which may be followed by a competency-based interview, background checks and references.

Special Notice

PSA holders do not hold international civil servant status, nor are they considered a “staff member” as defined in the UN Staff Rules and Regulations.

UNU is committed to diversity and inclusion within its workforce and encourages all candidates, irrespective of gender, nationality, religious and ethnic backgrounds, including persons living with disabilities, to apply and become part of the organization. Applications from developing countries and from women are strongly encouraged. Eligible internal applicants are also encouraged to apply.

UNU has a zero-tolerance policy on conduct that is incompatible with the aims and objectives of the United Nations and UNU, including sexual exploitation and abuse, sexual harassment, abuse of authority and discrimination.

Information about UNU rosters

UNU reserves the right to select one or more candidates from this vacancy announcement. We may also retain applications and consider candidates applying to this post for other similar positions with UNU.

Scam warning

UNU does not charge any application, processing, training, interviewing, testing or other fee in connection with the application or recruitment process. Should you receive a solicitation for the payment of a fee, please disregard it. Furthermore, please note that emblems, logos, names and addresses are easily copied and reproduced. Therefore, you are advised to apply particular care when submitting personal information on the web.

APPLY NOW

⚡ Looking for expert analysis, policy briefs, and high-level reviews on Nepal's health sector?

We are now offering premium subscription services to deliver timely, evidence-backed policy briefs, comprehensive technical reviews, and strategic analysis straight to your inbox. Tap into specialized consultant expertise and stay ahead on Nepal's emerging health strategies.

👉 [Contact Us]

Do you have a website? Looking for the best hosting provider? Here’s a discount code.

Latest Public Health Jobs

Latest Posts

July 25, 2023 0 comments

Newer Posts

Older Posts

Statement by Catherine Russell and Dr Tedros Adhanom Ghebreyesus

Background

Functions of the TAG on Maternal Mortality and Maternal Cause of Death Estimation

Operations of the TAG on Maternal Mortality and Maternal Cause of Death Estimation

Who can express interest?

WHO Model Lists of Essential Medicines

Lists of Essential Medicines

Overview

Study Fields

Human and Institutional Capacity:

Rights and Freedoms:

Sustainable Lands:

Thriving Communities:

Program Timeline

Eligibility Requirements

All applicants must

The Humphrey competition is not open to:

Visa sponsorship

About Institute (UNU-IIGH)

Key performance indicators

Qualifications

Remuneration

Duration of contract

Expected start date: 1 January 2024

How to Apply:

Application Deadline: 20 August 2023

PUBLIC HEALTH INITIATIVE